Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 145Carcinoma, Intraductal, Noninfiltrating 12Breast Carcinoma In Situ 10Neoplasm Metastasis 9Breast Neoplasms, Male 9Neoplasms 5Ovarian Neoplasms 4Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Gliosarcoma 3Glioma 3Glioblastoma 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Ductal, Breast 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Sarcoma 2Oligodendroglioma 2Multiple Endocrine Neoplasia Type 1 2Liver Neoplasms 2Hot Flashes 2Glioma, Subependymal 2Fibroadenoma 2Ependymoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Astrocytoma 2Thyroid Neoplasms 1

Interventions

Paclitaxel 2trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Letrozole 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cystadenocarcinoma, Serous × Tamoxifen × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡